143 related articles for article (PubMed ID: 31386865)
21. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
22. Bioequivalence of two lansoprazole delayed release capsules 30 mg in healthy male volunteers under fasting, fed and fasting-applesauce conditions: a partial replicate crossover study design to estimate the pharmacokinetics of highly variable drugs.
Thota S; Khan SM; Tippabhotla SK; Battula R; Gadiko C; Vobalaboina V
Drug Res (Stuttg); 2013 Nov; 63(11):551-7. PubMed ID: 23780504
[TBL] [Abstract][Full Text] [Related]
23. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
Fass R; Frazier R
Therap Adv Gastroenterol; 2017 Feb; 10(2):243-251. PubMed ID: 28203282
[TBL] [Abstract][Full Text] [Related]
24. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
Li YQ; Yan ZY; Zhang HW; Sun LN; Jiao HW; Wang MF; Yu LY; Yu L; Yuan ZQ; Meng L; Wang YQ
Eur J Clin Pharmacol; 2017 May; 73(5):547-554. PubMed ID: 28138748
[TBL] [Abstract][Full Text] [Related]
25. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Liu F; Shokrollahi H
Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
[TBL] [Abstract][Full Text] [Related]
26. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
27. Controlled release floating drug delivery system for proton pump inhibitors lansoprazole: In-vitro, In-vivo floating and pharmacokinetic evaluation.
Murad S; Mudassir J; Faiz S; Zahra A; Usman F; Farhan M; Arshad MS; Abbas N; Hussain A; Faran Ashraf Baig MM
Pak J Pharm Sci; 2022 Jan; 35(1(Supplementary)):195-201. PubMed ID: 35228177
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
29. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
Fock KM; Ang TL
Curr Opin Investig Drugs; 2008 Oct; 9(10):1108-15. PubMed ID: 18821474
[TBL] [Abstract][Full Text] [Related]
30. Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology.
Wu C; Sun L; Sun J; Yang Y; Ren C; Ai X; Lian H; He Z
Int J Pharm; 2013 Sep; 453(2):300-6. PubMed ID: 23806811
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.
Shin JM; Kim N
J Neurogastroenterol Motil; 2013 Jan; 19(1):25-35. PubMed ID: 23350044
[TBL] [Abstract][Full Text] [Related]
32. Dexlansoprazole - a new-generation proton pump inhibitor.
Skrzydło-Radomańska B; Radwan P
Prz Gastroenterol; 2015; 10(4):191-6. PubMed ID: 26759624
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
34. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
Horn JR; Howden CW
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():20-4. PubMed ID: 16303033
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
[TBL] [Abstract][Full Text] [Related]
36. Improving the solubility of dexlansoprazole by cocrystallization with isonicotinamide.
Li J; Wang L; Ye YQ; Fu X; Ren Q; Zhang H; Deng Z
Eur J Pharm Sci; 2016 Mar; 85():47-52. PubMed ID: 26836368
[TBL] [Abstract][Full Text] [Related]
37. Quality evaluation of extemporaneous delayed-release liquid formulations of lansoprazole.
Melkoumov A; Soukrati A; Elkin I; Forest JM; Hildgen P; Leclair G
Am J Health Syst Pharm; 2011 Nov; 68(21):2069-74. PubMed ID: 22011986
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.
Goh KL; Choi MG; Hsu PI; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Shetty V; Bocobo JC; Chan MM; Lin JT
J Neurogastroenterol Motil; 2016 Jul; 22(3):355-66. PubMed ID: 26932927
[TBL] [Abstract][Full Text] [Related]
39. Dexlansoprazole MR.
Aslam N; Wright R
Expert Opin Pharmacother; 2009 Oct; 10(14):2329-36. PubMed ID: 19708852
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs.
Patel H; Desai N; Patel P; Modi N; Soni K; Patel JR; Mistry GN; Patel JD; Chawla M; Srinivas NR
Drug Dev Ind Pharm; 2019 Sep; 45(9):1459-1467. PubMed ID: 31216902
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
